kaiser semaglutide criteria Population‐level impact of 2.4 mg in patients with obesity or overweight and cardiovascular disease: A modelling study based on the SELECT trial - Nanna - 2025 - Diabetes, Obesity and Metabolism 📌 Starting January 1, 2025,

Personalized Nutrition and Genetic Insights on PlexusDx The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month) analyzes GLP1R (rs6923761), GIPR (rs1800437), FTO (rs9939609), and MC4R (rs17782313) variants that relate to GLP-1 and related signaling pathways

Longer-term studies show even greater weight reduction over several months

Chronic inflammation in post-acute sequelae of COVID-19 modulates gut microbiome: a review of literature on COVID-19 sequelae and gut dysbiosis

Patients who taper off successfully often retain their results with ongoing guidance and support

Clinicians should consider several potential concerns during evaluation: Unknown active ingredient source Variable potency or concentration Differences in excipients Sterility concerns for injectable products Dosing inaccuracies Limited stability data Inconsistent patient instructions The FDA has also warned healthcare professionals about compounded products made with salt forms of semaglutide that differ from the approved active ingredient

Unlike PDE-5 inhibitors, it acts directly on the central nervous system via melanocortin pathways